Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine in Treating Bipolar Disorder Comorbid With Alcoholism
NCT03043001Phase 3
Key facts
- Status
- Unknown
- Start
- Jan 2014
- Primary completion
- Dec 2016
- Countries
- 1
- Sponsor
- National Cheng Kung University Hospital
- Modality
- Small Molecules
- Drugs
- memantine
- Conditions
- bipolar disorder (BD)alcohol dependence
01
Overview
Phase 3, randomised, double-blind trial of memantine in bipolar disorder (BD) and alcohol dependence, sponsored by National Cheng Kung University Hospital. Primary endpoint: Change in plasma Brain-Derived Neurotropic Factor (BDNF) at week 12. Status: unknown.
02
Design
1 arm- Study design
- RandomizedDouble-blind
add-on memantine therapy
Patients receive regular treatment with add-on memantine medication for 12 weeks.
03
Who it enrols
Adults aged 18-65 with bipolar disorder and alcohol dependence, excluding pregnant/nursing women, those with poorly controlled medical conditions, or recent use of memantine, anti-inflammatories, or ECT.
04
Endpoints
Primary
Change in plasma Brain-Derived Neurotropic Factor (BDNF)
Secondary
Change in attention
Change in side effects
Change in cytokine levels
Beyond the preview
Go deeper on NCT03043001.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043001.